Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionCytotoxic prodrug chemically linked with a human anti-CD70 antibody
Molecular Target CD70 (CD27L)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPhase I
Standard Indication Cancer (unspecified)
Indication DetailsTreat advanced/recurrent renal cell carcinoma (RCC) and/or relapsed/refractory B cell non-Hodgkin's lymphoma (NHL)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today